Separate HIV-1 and HIV-2 Detection with Dedicated Result Lines in 15 Minutes: Why an IVDR-Class-D Rapid Test Belongs in Every Screening Portfolio
Early HIV detection saves lives. The sooner a person knows their status, the sooner they can access life-saving antiretroviral therapy, reduce viral load to undetectable levels, and prevent onward transmission. For healthcare systems and IVD distributors worldwide, the question is no longer whether to offer HIV rapid testing — it is which test delivers the best combination of clinical performance, regulatory compliance, and market differentiation.
NewScen’s HIV (1+2) Antibody Rapid Test answers that question with a three-line design that detects HIV-1 and HIV-2 antibodies separately and displays each result on its own dedicated line, backed by IVDR Class D certification and independently validated performance data.
A Three-Line Test That Detects HIV-1 and HIV-2 Separately
Most HIV rapid tests on the market deliver a binary result: reactive or non-reactive. They tell you that antibodies are present, but not which type. That distinction matters.
HIV-1 and HIV-2 differ in epidemiology, disease progression, and clinical management. HIV-2, concentrated in West Africa and increasingly seen in Europe and North America through migration, has a slower progression and different resistance profiles. Being able to detect HIV-1 and HIV-2 separately and display each result on its own line at the screening stage gives clinicians and public health programs actionable information — not just a label.
NewScen’s test uses separately precoated recombinant antigens:
- Zone 1: HIV-1 antigens (gp41, gp120)
- Zone 2: HIV-2 antigen (gp36)
- Zone C: Built-in procedural control
A red line in Zone 1 indicates HIV-1 antibodies; a line in Zone 2 indicates HIV-2; both lines indicate co-infection or cross-reactive antibodies. The control line confirms the assay ran correctly. This is a genuinely differentiated solution for professional screening programs and diagnostic distribution channels.
Performance Backed by Data, Not Just Claims
A rapid test is only as good as its validation data. Here is what the clinical evaluation shows:
Sensitivity: 100%
Across 500 positive specimens — including HIV-1 serum/plasma, whole-blood/plasma matched pairs, non-B-subtype HIV-1 (subtypes A, A1, A2, C, CRF01_AE, CRF02_AG, CRF06_cpx, CRF36_cpx, D, F1, F2, G, H, J,K, and Group O), and HIV-2 samples — the test achieved 100% sensitivity. Zero false negatives.
| Specimen Group | n | Positive Detected | Sensitivity |
| HIV-1 Ab positive (serum/plasma) | 260 | 260 | 100% |
| HIV-1 Ab positive (whole blood/plasma couples) | 100 | 100 | 100% |
| Non-B-subtype HIV-1 Ab positive (plasma) | 40 | 40 | 100% |
| HIV-2 Ab positive (serum/plasma) | 100 | 100 | 100% |
| Total | 500 | 500 | 100% |
Seroconversion: Earlier Detection Than Reference Methods
In an evaluation of 31 commercially available seroconversion panels (233 panel members total), NewScen’s test detected 74 positive members, compared with 70 detected by the reference tests. Earlier detection during the window period means fewer missed infections at the critical early stage.
Specificity: 99.82%
Across 1,700 negative specimens — including unselected blood donors, venous whole-blood donations, and hospitalized patients — specificity reached 99.82% (1,697 true negatives out of 1,700). High specificity reduces the anxiety and follow-up burden of false-positive results.
Cross-Reactivity and Interference: Minimal Risk
The test was challenged with 320 specimens containing potentially cross-reactive substances — pregnant women, anti-HBs, anti-HBc, anti-HCV, anti-HTLV I/II, anti-HEV, rheumatoid factor, CMV, EBV, malaria, syphilis, herpes, and anti-E. coli antibodies. Only one false positive occurred (in a pregnant-woman sample), and no cross-reactivity was observed with any of the infectious-disease markers tested.
Endogenous interferents (rheumatoid factor, late-pregnancy serum, high AFP, hyperlipemia, high bilirubin, hemolysis) and exogenous interferents (heparin, sodium citrate, EDTA, sodium azide, and antiretroviral drugs including abacavir, lamivudine, tipranavir, and efavirenz) showed no effect on test performance.
Reproducibility: 100% Across Operators, Sites, and Lots
A rigorous reproducibility study — 10 operators, 5 separate sites, 5 runs per day, 5 consecutive days, 3 different lots — yielded 100% consistency. Sample-type consistency was also 100% across whole blood, serum, and plasma from the same donors, and fingerstick versus venous blood showed 100% coincidence (55 positive, 65 negative matched pairs).
IVDR Class D: Compliance That Opens Doors
The NewScen HIV (1+2) Antibody Rapid Test is classified as IVDR Class D — the highest-risk category for in vitro diagnostics under EU Regulation 2017/746. Class D products include tests for infectious diseases that may be life-threatening, and they require the most stringent conformity assessment route (Annex IX, full quality assurance plus technical documentation review by a Notified Body).
What does IVDR Class D mean for distributors and procurement partners?
- EU market access: A CE-marked Class D product can be placed on the EU market and referenced in tenders that require IVDR compliance.
- Tender eligibility: Many hospital networks, national health services, and international procurement organizations (e.g., the Global Fund, PEPFAR-adjacent programs) now require IVDR-compliant IVDs.
- Regulatory credibility: Class D status signals that the product has passed a rigorous, independent review — a strong differentiator in markets where self-certified or older CE-IVD products are being phased out.
- Future-proofing: As the IVDR transition deadline has passed and legacy CE-IVD products lose validity, an IVDR-certified portfolio avoids supply gaps.
The product is manufactured under ISO 9001:2015 and ISO 13485:2016 certified quality systems, with CE marking under Notified Body 0123.
Built for Professional Use Across Multiple Settings
The HIV (1+2) Antibody Rapid Test is intended for professional laboratory use only and is suitable for:
- Hospitals and clinical laboratories
- Clinics and outpatient centers
- Public health and community HIV screening programs
- Infectious disease screening in high-prevalence settings
- Distributor-led local market evaluation and registration
How It Works
- Remove the cassette from its foil pouch and place it on a flat, clean surface (use within 1 hour).
- Add 1 drop (30–40 µL) of specimen — serum, plasma, venous whole blood, or fingerstick whole blood — to the sample well (S).
- Add 1 drop (45–55 µL) of diluent buffer vertically to the sample well.
- Read the result between 15 and 30 minutes.
No specialized equipment, no cold chain required for storage (4–30°C, 24-month shelf life), and no automated platform needed.
Flexible Packaging for Every Channel
| Catalog No. | Format |
| HIV3-29200111000 | 1 test(with lancet & alcohol pad) |
| HIV3-29200201000 | 2 tests(with lancet & alcohol pad) |
| HIV3-29200501000 | 5 tests (with lancet & alcohol pad) |
| HIV3-29202511000 | 25 tests |
| HIV3-29204017000 | 40 tests |
The 1T/2T/5T formats include sterile lancets and alcohol pads for fingerstick use, while the 25T and 40T lab packs are optimized for high-throughput professional settings.
Why Distributors Choose NewScen
For IVD distributors and local partners, this product offers a rare combination:
- Product differentiation: separate HIV-1 and HIV-2 detection with dedicated result lines on a single rapid test is not commodity — it is a conversation starter with hospital lab directors and public health buyers.
- Compliance value: IVDR Class D + CE 0123 + ISO 13485 gives tenders and regulatory submissions a strong foundation.
- Performance credibility: 100% sensitivity, 99.82% specificity, and 100% reproducibility are numbers that hold up in procurement reviews.
- Partner support: NewScen provides product information, technical documents, regulatory dossiers, IFUs, samples for local evaluation, and supply-chain support for registration preparation.
- Supply reliability: Manufactured by NewScen Coast Bio-Pharmaceutical Co., Ltd. in Tianjin, China, with a European Authorized Representative (Wellkang Ltd., UK) and established export infrastructure.
The Bottom Line
HIV testing remains the cornerstone of prevention, treatment-as-prevention, and infection control. A rapid test that combines separate HIV-1 and HIV-2 detection with individually displayed results, IVDR Class D compliance, and clinically validated performance is more than a SKU — it is a strategic asset for any distributor serving the infectious-disease rapid-test market.
If you are evaluating HIV rapid test manufacturers or building an IVDR-compliant infectious-disease portfolio, NewScen welcomes the opportunity to support your market with samples, documentation, and long-term supply partnership.
Contact: export@newscen.com
Website: www.newscenbiotech.com
Product page: https://newscenbiotech.com/product/hiv-1-2-tri-line-rapid-test-ce-ivdr-class-d/
